The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy
Open accessAbstract
Purpose: To determine whether a dose of 78 Gy improves outcome compared with a conventional dose of 68 Gy for prostate cancer patients treated with three-dimensional conformal radiotherapy. Patients and Methods: Between June 1997 and February 2003, stage T1b-4 prostate cancer patients were enrolled onto a multicenter randomized trial comparing 68 Gy with 78 Gy. Patients were stratified by institution, age, (neo)adjuvant hormonal therapy (HT), and treatment group. Four treatment groups (with specific radiation volumes) were defined based on the probability of seminal vesicle involvement. The primary end point was freedom from failure (FFF). Failure was defined as clinical failure or biochemical failure, according to the American Society of Therapeutic Radiation Oncology definition. Other end points were freedom from clinical failure (FFCF), overall survival (OS), and toxicity. Results: Median follow-up time was 51 months. Of the 669 enrolled patients, 664 were included in the analysis. HT was prescribed for 143 patients. FFF was significantly better in the 78-Gy arm compared with the 68-Gy arm (5-year FFF rate, 64% v 54%, respectively), with an adjusted hazard ratio of 0.74 (P = .02). No significant differences in FFCF or OS were seen between the treatment arms. There was no difference in late genitourinary toxicity of Radiation Therapy Oncology Group and European Organisation for Research and Treatment of Cancer grade 2 or more and a slightly higher nonsignificant incidence of late gastrointestinal toxicity of grade 2 or more. Conclusion: This multicenter randomized trial shows a significantly improved FFF in prostate cancer patients treated with a higher dose of radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prescribing, recording, and reporting photon beam therapy
Icru (1993) · Medical Entomology and Zoology · Cited by 1,996
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E., von Eschenbach, A. C., Kuban, D. A., & Rosen, I. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02829-8 · Cited by 1,333
Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., & Walsh, P. C. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35410-1 · Cited by 1,278
Zietman, A. L., DeSilvio, M. L., Slater, J. D., Rossi, C. J., Miller, D. W., Adams, J. A., & Shipley, W. U. (2005) · JAMA · doi:10.1001/jama.294.10.1233 · Cited by 1,224
Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer
Early Breast Cancer Trialists' Collaborative Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198812293192601 · Cited by 933
Zelefsky, M., Leibel, S., Gaudin, P., Kutcher, G., Fleshner, N., Venkatramen, E. S., Reuter, V., Fair, W., Ling, C. C., & Fuks, Z. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00091-1 · Cited by 924
Dearnaley, D. P., Khoo, V. S., Norman, A. R., Meyer, L., Nahum, A., Tait, D., Yarnold, J., & Horwich, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05180-0 · Cited by 739
Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer
Zelefsky, M. J., Fuks, Z., Happersett, L., Lee, H. J., Ling, C. C., Burman, C. M., Hunt, M., Wolfe, T., Venkatraman, E. S., Jackson, A., et al. (2000) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00100-0 · Cited by 543
Pollack, A., Zagars, G. K., Smith, L. G., Lee, J. J., von Eschenbach, A. C., Antolak, J. A., Starkschall, G., & Rosen, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3904 · Cited by 521
Peeters, S. T. H., Heemsbergen, W. D., van Putten, W. L. J., Slot, A., Tabak, H., Mens, J. W., Lebesque, J. V., & Koper, P. C. M. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.07.715 · Cited by 445
Self-citationShipley, W. U., Verhey, L. J., Munzenrider, J. E., Suit, H. D., Urie, M. M., McManus, P. L., Young, R. H., Shipley, J. W., Zietman, A. L., Biggs, P. J., et al. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00063-5 · Cited by 407
Dose selection for prostate cancer patients based on dose comparison and dose response studies
Hanks, G. E., Hanlon, A. L., Pinover, W. H., Horwitz, E. M., Price, R., & Schultheiss, T. E. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00498-8 · Cited by 156
Koper, P. C. M., Jansen, P. P., van Putten, W., van Os, M., Wijnmaalen, A., Lebesque, J. V., & Levendag, P. C. (2004) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2004.07.020 · Cited by 100
Self-citationPickles, T., Kim‐Sing, C., Morris, W. J., Tyldesley, S. K., & Paltiel, C. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00439-5 · Cited by 87
Symon, Z., Griffith, K. A., McLaughlin, P. W., Sullivan, M., & Sandler, H. M. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00569-8 · Cited by 74
Kupelian, P. A., Buchsbaum, J. C., Reddy, C. A., & Klein, E. A. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01466-3 · Cited by 55
Comparison of prostate cancer treatment in two institutions: a quality control study
Rasch, C. R. N., Remeijer, P., Koper, P. C. M., Meijer, G. J., Stroom, J. C., van Herk, M., & Lebesque, J. V. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00280-1 · Cited by 42
Self-citationConnell, P. P., Ignacio, L., McBride, R. B., Weichselbaum, R. R., & Vijayakumar, S. (1999) · Urology · doi:10.1016/s0090-4295(99)00253-8 · Cited by 36
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Mottet, N., Schmid, H.-P., van der Kwast, T., Wiegel, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.10.039 · Cited by 1,492
Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., Lee, A. K., & Pollack, A. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.054 · Cited by 1,232
Dearnaley, D. P., Sydes, M. R., Graham, J. D., Aird, E. G., Bottomley, D., Cowan, R. A., Huddart, R. A., Jose, C. C., Matthews, J. H., Millar, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70143-2 · Cited by 905
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Metadata
- Authors
- Peeters, S. T. H., Heemsbergen, W. D., Koper, P. C. M., van Putten, W. L. J., Slot, A., Dielwart, M. F. H., Bonfrer, J. M. G., Incrocci, L., & Lebesque, J. V.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-05-01
- Volume
- 24
- Issue
- 13
- Pages
- 1990-1996
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097532477
- Cited by
- 966
- References
- 19
- FWCI
- 50.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.